All News

Japan Introduces Weekly Leqembi Pen for Early Alzheimer’s

By Sandy Martin•November 16, 2026

Japan has introduced a weekly subcutaneous Leqembi pen for mild cognitive impairment and mild dementia due to Alzheimer’s. Regulatory evidence supports the 500 mg dose through drug-exposure bridging, changing delivery while retaining specialist monitoring.

Japan now has a commercially available subcutaneous pen formulation of Leqembi, or lecanemab, for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. An LT Wire report on the rollout says Eisai and Biogen made the product available on November 12, 2026.

Japan’s Pharmaceuticals and Medical Devices Agency approved the pen on September 16, 2026, and records its marketing start as November 2026. The PMDA product listing specifies a dose of 500 mg once weekly, delivered using two pens containing 250 mg each.

The development changes how lecanemab can be administered, rather than expanding what the medicine is approved to do. The indication remains slowing progression in the early symptomatic stages of Alzheimer’s disease, according to the Japanese regulatory record. It is not an approval for general memory loss, cognitive ageing or Alzheimer’s prevention.

A different route for the same active medicine

Leqembi Pen contains the same active ingredient as other lecanemab presentations but delivers it by injection under the skin. Each weekly dose requires two separate pens, an important distinction from a single-device dose.

Changing the route of administration can alter the practical demands surrounding treatment. A subcutaneous injection does not inherently require intravenous access or an infusion chair, although the regulatory records supplied for the Japanese product do not establish how individual health systems or clinics will organize each dose. The total effect on travel, staffing and caregiver burden will therefore depend on implementation, not simply on the existence of a pen.

This distinction matters because convenience is not itself a clinical outcome. The approval establishes a new way to deliver an indicated Alzheimer’s medicine; it does not show that the pen improves cognition more than another lecanemab presentation, produces better adherence or reduces the overall burden of care.

For patients and families navigating early Alzheimer’s treatment, however, delivery is not a trivial detail. Weekly injections create a different rhythm from an infusion-based service, with implications for scheduling, refrigerated storage and coordination with the clinical monitoring that accompanies lecanemab.

How the 500 mg pen was connected to existing evidence

The evidence supporting the marketed pen is best understood as a regulatory bridge rather than a standalone clinical-outcome trial of this exact product in people starting treatment for the first time.

In its appropriate-use guide for the subcutaneous formulation, PMDA states that the approved 500 mg weekly pen regimen produces drug exposure similar to the evaluated subcutaneous regimen. Drug exposure describes how much medicine the body encounters over time. Comparable exposure can support the expectation that a new presentation delivers an appropriate amount of the active medicine, but it is not the same measurement as change in cognition or daily functioning.

The composition of the evidence is also relevant. All participants who received the pen formulation had previously received lecanemab. Evidence in treatment-naive participants—people who had not previously received the medicine—came from a 720 mg subcutaneous regimen administered from a vial, rather than the marketed 500 mg pen regimen.

This does not negate the approval. It explains how the regulator connected the device and dose to the wider lecanemab development program. The available official records do not provide a peer-reviewed trial independently measuring clinical outcomes in previously untreated patients who began therapy with the exact 500 mg pen presentation.

The proportionate interpretation is therefore that the pen is an approved delivery option backed by pharmacokinetic and linked clinical evidence. It should not be treated as a newly demonstrated improvement in Alzheimer’s outcomes beyond the established therapeutic claim for lecanemab.

Safety monitoring remains part of the treatment

Moving administration under the skin does not remove the principal monitoring demands associated with lecanemab. Of particular importance are amyloid-related imaging abnormalities, or ARIA, a term for changes detected on brain imaging that can involve swelling or areas of bleeding.

PMDA safety information states that ARIA occurs more commonly during the first 14 weeks after lecanemab is started and recommends especially careful monitoring during this period. That early-treatment pattern is relevant when interpreting the pen evidence, because participants who received the pen had already been exposed to lecanemab.

In other words, experience in people switching to a pen cannot automatically answer every question about beginning treatment with that presentation. The approved route may change the mechanics of drug delivery, but it does not turn lecanemab into a low-monitoring medicine or separate the product from the established safety-management pathway.

This is also why the pen should not be understood as an over-the-counter-style convenience product. Its role remains within disease-specific clinical care, where eligibility, treatment initiation and imaging surveillance are managed around the individual patient.

Two injections, cold storage and a defined indication

The practical instructions are unusually important for understanding what the new format entails. The approved 500 mg weekly dose consists of two 250 mg injections. Permitted sites include the thigh, abdomen and back of the upper arm. The two pens should not be injected within three centimetres of one another, and injection sites should be rotated.

The pens must be refrigerated at 2–8°C, and the product has a stated shelf life of two years. Those requirements preserve a cold-chain obligation even though the route no longer depends on intravenous delivery. Clinics and other treatment services must also account for two devices per weekly dose rather than one.

For patients and caregivers, the meaningful questions will be operational: where doses are administered, who handles the devices, how refrigeration is maintained and how weekly treatment fits alongside imaging and clinical follow-up. The approval record describes the product and its use but does not, by itself, demonstrate that every patient will receive treatment at home or that the pen will lower overall care demands.

For the biotechnology sector, Japan’s decision illustrates how a mature biologic can acquire a materially different presentation through a regulatory package that connects pharmacokinetic exposure, prior treatment experience and the broader clinical program. For Alzheimer’s services, its importance is more immediate: a medicine already used in early symptomatic disease can now be delivered in a weekly subcutaneous format, while retaining a narrow indication and the need for structured safety monitoring.